Mylan, Takeda Bury Hatchet In Diabetes Drug Feud

By Ryan Davis

Law360, New York (March 17, 2010, 2:45 PM ET) -- Mylan Inc. has resolved two patent infringement suits brought by Takeda Pharmaceutical Co. Ltd. over plans to market generic versions of diabetes drugs Actos and Actoplus Met.

Mylan said in a statement Tuesday that it had reached settlements with Takeda, bringing a close to litigation in the U.S. District Court for the Southern District of New York. A representative for Takeda confirmed the deals, but declined to comment further.

According to the defendant, the settlements allow it to begin marketing generic Actos on Aug. 17, 2012...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles